Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial

References

• Attal M, Harousseau J L, Stoppa A M, Sotto J J, Fuzibet J G, Rossi J F, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996; 335: 91–97
   PubMed Web of Science ®Google Scholar
• Child J A, Morgan G I, Davies F E, Owen R G, Bell S E, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883
   PubMed Web of Science ®Google Scholar
• Harousseau J L, Moreau P, Attal M, Facon T, Avet-Loiseau H. Stem-cell transplantation in multiple myeloma. Best Pract Res Clin Haematol 2005; 18: 603–618
   PubMed Web of Science ®Google Scholar
• Kyle R A. Five decades of therapy for multiple myeloma: a paradigm for therapeutic models. Leukemia 2005; 19: 910–912
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Vesole D, Naucke S, Cheson B, Mattox S, et al. Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant 1998; 21: 1101–1107
   PubMed Web of Science ®Google Scholar
• Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731–735
   PubMed Web of Science ®Google Scholar
• Mansi J, Da Costa F, Viner C, Judson J, Gore M, Cunnigham D. High-dose busulfan in patients with myeloma. J Clin Oncol 1992; 10: 1569–1573
   PubMed Web of Science ®Google Scholar
• Alegre A, Lamana M, Arranz R, Fernández-Villa M J, Tomás J F, Figuera A, et al. Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. Br J Haematol 1995; 91: 380–386
   PubMed Web of Science ®Google Scholar
• Bensinger W I, Rowley S D, Demirer T, Lilleby K, Schiffman K, Chauncey T, et al. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol 1996; 145: 1447–1456
   Google Scholar
• Benson D M, Elder P J, Lin T S, Blum W, Penza S, Avalos B, et al. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimen for autologous stem cell transplantation in patients with multiple myeloma. Leuk Res 2007; 31: 1069–1075
   PubMed Web of Science ®Google Scholar
• Anderson K C, Shaughnessy J D, Barlogie B, Harousseau J L, Rodman G D. Multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2002; 21: 4–40
   Google Scholar
• Lahuerta J J, Martínez J, Grande C, Bladé J, de la Serna J, Alegre A, et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in multiple myeloma. Br J Haematol 2000; 109: 138–147
   PubMed Web of Science ®Google Scholar
• Carrera E, Rosiñol L, Terol M J, Alegre A, de Arriba F, García-Laraña J, et al. Spanish Myeloma Group/PETHEMA. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant 2007; 13: 1448–1454
   PubMed Web of Science ®Google Scholar
• Shimoni A, Bicliorai B, Toren A, Hardan I, Avigdor A, Yeshurun M, et al. Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation. Myeloablation with reduced toxicity. Exp Hematol 2003; 31: 428–434
   PubMed Web of Science ®Google Scholar
• Kashyap A, Wingard J, Cagnoni P, Tarantolo S, Hu W, Blume K, et al. Intravenous versus oral busulfan as part of busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002; 8: 493–500
   PubMed Web of Science ®Google Scholar
• Andersson B S, Ashyap A, Gian V, Wingard J, Fernandez H, Cagnoni P, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002; 8: 145–154
   PubMed Web of Science ®Google Scholar
• Aggarwal C, Gupta S, Vaughan W P, Saylors G B, Salzman D E, Katz R O, et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 2006; 12: 770–777
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Giralt S, Madden T, Thapar N, Shpall E, Hosing C, et al. Toxicity and early response after intravenous (IV) busulfan (Bu) plus melphalan (Mel) conditioning for autologous stem cell transplantation (SCT) in patients (pts) with multiple myeloma (MM). Blood 2006; 108(Suppl 1)2943a
   Google Scholar
• Fernandez H F, Tran H T, Albrecht F, Lennon S, Caldera H, Goodman M S. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 486–492
   PubMed Web of Science ®Google Scholar
• Russell J A, Tran H T, Quinlan D, Chaudhry A, Duggan P, Brown C, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468–476
   PubMed Web of Science ®Google Scholar
• Bearman S I, Appelbaum F R, Buckner C D, Petersen F B, Fisher L D, Clift R A, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568
   PubMed Web of Science ®Google Scholar
• Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gharton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123
   PubMed Web of Science ®Google Scholar
• Cavo M, Tosí P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25: 2434–2441
   PubMed Web of Science ®Google Scholar
• Kyle R A, Rajkumar S V. Multiple myeloma. N Engl J Med 2004; 351: 186–173
   Web of Science ®Google Scholar
• Reich G, Mapara M Y, Reichardt P, Dörken B, Maschmeyer G. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant 2001; 27: 525–529
   PubMed Web of Science ®Google Scholar
• Auner H W, Sill H, Mulabecirovic A, Linkesch W, Krause R. Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma. Ann Hematol 2002; 81: 374–377
   PubMed Web of Science ®Google Scholar
• Puig N, de la Rubia J, Jarque I, Salavert M, Montesinos P, Sanz J, et al. A study of incidence and characteristics of infections in 476 patients from a single center undergoing autologous blood stem cell transplantation. Int J Hematol 2007; 86: 186–192
   PubMed Web of Science ®Google Scholar
• Kolbe K, Domkin D, Derings H G, Bhakdi S, Huber C, Aulitzky W E, et al. Infections complications during neutropenia subsequent peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 143–147
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Olivieri A, Rupoli S, Frayfer J, Mele A, et al. Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. Bone Marrow Transplant 1999; 24: 1079–1087
   PubMed Web of Science ®Google Scholar
• Durie B. New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals. Clin Lymphoma Myeloma 2005; 6: 181–190
   PubMedGoogle Scholar
• Attal M, Harousseau J L, Facon T, Guilhot E, Doyen C, Fuzibet J G, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G, Anaisie E, Shaughnessy J, Rasmissen E, Van Rhee F, et al. Thalidomide and hematopoietic cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030
   PubMed Web of Science ®Google Scholar